Aequus Pharmaceuticals Inc.
AQS.V
TSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 68.17% | 33.64% | 304.87% | 324.06% | 987.00% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 68.17% | 33.64% | 304.87% | 324.06% | 987.00% |
| Cost of Revenue | 62.73% | 26.38% | 383.08% | 377.68% | 584.62% |
| Gross Profit | 73.42% | 42.05% | 267.18% | 302.30% | 2,413.64% |
| SG&A Expenses | -65.11% | -73.25% | -67.40% | -37.03% | -12.50% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -51.73% | -62.74% | -55.49% | -28.22% | -12.81% |
| Operating Income | 84.14% | 86.27% | 86.53% | 55.16% | 30.20% |
| Income Before Tax | 159.68% | 76.26% | 8.47% | 70.43% | 24.78% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 159.68% | 76.26% | 8.47% | 70.43% | 24.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 159.68% | 76.26% | 8.47% | 70.43% | 24.78% |
| EBIT | 84.14% | 86.27% | 86.53% | 55.16% | 30.20% |
| EBITDA | -- | -- | -- | 55.31% | 30.23% |
| EPS Basic | 158.82% | 76.32% | 8.11% | 70.00% | 24.44% |
| Normalized Basic EPS | 76.19% | 75.00% | 78.26% | 44.00% | 25.00% |
| EPS Diluted | 158.82% | 76.32% | 8.11% | 70.00% | 24.44% |
| Normalized Diluted EPS | 76.19% | 75.00% | 78.26% | 44.00% | 25.00% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |